As filed with the Securities and Exchange Commission on February 23, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
Relay Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
47-3923475 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
399 Binney Street, 2nd Floor
Cambridge, MA 02139
(617) 370-8837
(Address of Principal Executive Offices)
Relay Therapeutics, Inc. 2020 Stock Option and Incentive Plan
Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan
(Full Title of the Plans)
Sanjiv K. Patel
President and Chief Executive Officer
Relay Therapeutics, Inc.
399 Binney Street, 2nd Floor
Cambridge, MA 02139
(617) 370-8837
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
William Collins, Esq.
Gabriela Morales-Rivera, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer |
|
☒ |
Accelerated filer |
☐ |
Non-accelerated filer |
|
☐ |
Smaller reporting company |
☐ |
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
This Registration Statement on Form S-8 is being filed for the purpose of registering (i) an additional 6,056,111 shares of common stock, par value $0.001 per share (“Common Stock”) of Relay Therapeutics, Inc. (the “Registrant”) to be issued under the Registrant’s 2020 Stock Option and Incentive Plan, as amended (the “2020 Plan”) and (ii) an additional 1,211,222 shares of Common Stock of the Registrant to be issued under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”), for which Registration Statements on Form S-8 relating to the same employee benefit plans are effective.
Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on July 17, 2020 (File No. 333-239912), March 25, 2021 (File No. 333-254704), and February 24, 2022 (File No. 333-262974) related to the 2020 Plan and the 2020 ESPP are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
|
|
|
4.1 |
|
|
|
|
|
4.2 |
|
|
|
|
|
4.3 |
|
|
|
|
|
4.4 |
|
|
|
|
|
5.1* |
|
|
|
|
|
23.1* |
|
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm |
|
|
|
23.2* |
|
|
|
|
|
24.1* |
|
|
|
|
|
99.1 |
|
|
|
|
|
99.2 |
|
|
|
|
|
107* |
|
|
* |
Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on the 23rd day of February, 2023.
|
|
|
RELAY THERAPEUTICS, INC. |
||
|
|
|
By: |
|
/s/ Sanjiv K. Patel |
|
|
Sanjiv K. Patel, M.D. |
|
|
President and Chief Executive Officer (Principal Executive Officer) |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Sanjiv K. Patel, M.D. and Brian Adams as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/ Sanjiv K. Patel |
|
President, Chief Executive Officer and Director |
|
February 23, 2023 |
Sanjiv K. Patel, M.D. |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Thomas Catinazzo |
|
Chief Financial Officer |
|
February 23, 2023 |
Thomas Catinazzo |
|
(Principal Accounting Officer and Principal Financial Officer) |
|
|
|
|
|
|
|
/s/ Alexis Borisy |
|
Director |
|
February 23, 2023 |
Alexis Borisy |
|
|
|
|
|
|
|
|
|
/s/ Linda A. Hill |
|
Director |
|
February 23, 2023 |
Linda A. Hill, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/ Douglas S. Ingram |
|
Director |
|
February 23, 2023 |
Douglas S. Ingram |
|
|
|
|
|
|
|
|
|
/s/ Sekar Kathiresan |
|
Director |
|
February 23, 2023 |
Sekar Kathiresan, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Mark Murcko |
|
Director |
|
February 23, 2023 |
Mark Murcko, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/ Jami Rubin |
|
Director |
|
February 23, 2023 |
Jami Rubin |
|
|
|
|
|
|
|
|
|
/s/ Laura Shawver |
|
Director |
|
February 23, 2023 |
Laura Shawver, Ph.D. |
|
|
|
|
|
|
|
|
|
Exhibit 5.1
|
|
|
Goodwin Procter llp 100 Northern Avenue goodwinlaw.com +1 617 570 1000 |
February 23, 2023
Relay Therapeutics, Inc.
399 Binney Street, 2nd Floor
Cambridge, MA 02139
Re: Securities Being Registered under Registration Statement on Form S-8
We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the “Registration Statement”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), on or about the date hereof relating to an aggregate of 7,267,333 shares (the “Shares”) of Common Stock, $0.001 par value per share (“Common Stock”), of Relay Therapeutics, Inc., a Delaware corporation (the “Company”), that may be issued pursuant to the Company’s 2020 Stock Option and Incentive Plan, as amended, and 2020 Employee Stock Purchase Plan (collectively, the “Plans”).
We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.
The opinion set forth below is limited to the Delaware General Corporation Law.
For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.
Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.
This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019).
We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.
|
Very truly yours, /s/ GOODWIN PROCTER LLP
GOODWIN PROCTER LLP |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2020 Stock Option and Incentive Plan and 2020 Employee Stock Purchase Plan of Relay Therapeutics, Inc. of our reports dated February 23, 2023, with respect to the consolidated financial statements of Relay Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Relay Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 23, 2023
Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Relay Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount to be Registered(1) |
Proposed Maximum Offering Price per Share |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee |
||||||
Equity |
Common Stock, $0.001 par value per share |
Other (2) |
6,056,111 shares (3) |
$ |
17.82 (2) |
|
$ |
107,919,898.02 |
(2) |
$ |
0.00011020 |
$ |
11,892.78 |
Equity |
Common Stock, $0.001 par value per share |
Other (4) |
1,211,222 shares (5) |
$ |
15.15 (4) |
|
$ |
18,350,013.30 |
(4) |
$ |
0.00011020 |
$ |
2,022.18 |
Total Offering Amounts |
|
|
|
$ |
126,269,911.32 |
|
|
|
|
— |
|||
Total Fees Previously Paid |
|
|
|
|
|
|
|
|
|
— |
|||
Total Fee Offsets |
|
|
|
|
|
|
|
|
|
— |
|||
Net Fee Due |
|
|
|
|
|
|
|
|
$ |
13,914.96 |
|||
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover any additional shares of common stock, $0.001 par value per share (“Common Stock”) which become issuable under the Registrant’s 2020 Stock Option and Incentive Plan, as amended (the “2020 Plan”) and the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”), by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant’s outstanding shares of Common Stock. |
(2) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based upon the average of the high and low prices reported for the Common Stock on the Nasdaq Global Market on February 22, 2023. |
(3) |
Represents shares of Common Stock that were added to the shares authorized for issuance under the 2020 Plan, effective as of January 1, 2023 pursuant to an “evergreen” provision contained in the 2020 Plan. Pursuant to such provision, an additional number of shares will automatically be added to the shares authorized for issuance under the 2020 Plan on January 1 of each year. Shares available for issuance under the 2020 Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on July 17, 2020 (File No. 333-239912), March 25, 2021 (File No. 333-254704), and February 24, 2022 (File No. 333-262974). |
(4) |
The price of $15.15 per share, which is 85% of the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Global Market on February 22, 2023, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act of 1933, as amended, and has been used as these shares are without a fixed price. Pursuant to the 2020 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of the offering period or on the exercise date, whichever is less. |
(5) |
Represents shares of Common Stock that were added to the shares authorized for issuance under the 2020 ESPP, effective as of January 1, 2023 pursuant to an “evergreen” provision contained in the 2020 ESPP. Pursuant to such provision, an additional number of shares will automatically be added to the shares authorized for issuance under the 2020 ESPP on January 1 of each year. Shares available for issuance under the 2020 ESPP were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on July 17, 2020 (File No. 333-239912), March 25, 2021 (File No. 333-254704), and February 24, 2022 (File No. 333-262974). |